Inositol Supplementation in Women Without PCOS
There is emerging evidence that myo-inositol supplementation may provide modest benefits for women without PCOS undergoing IVF by reducing gonadotropin requirements, though it does not improve pregnancy outcomes. For other indications in non-PCOS women, the evidence supports specific uses in pregnancy-related conditions.
IVF and Ovarian Stimulation
Myo-inositol reduces the total dose of gonadotropins needed during controlled ovarian stimulation in non-PCOS women undergoing IVF. 1
- A meta-analysis demonstrated that myo-inositol supplementation significantly decreased gonadotropin amounts required in non-PCOS women (p = 0.02), though the reduction in stimulation length was not significant in this population 1
- A pilot study of 100 non-PCOS women found that pretreatment with myo-inositol plus folic acid for 3 months before IVF resulted in significantly lower total gonadotropin doses compared to folic acid alone 2
- The same study showed a reduction in the number of oocytes retrieved, but clinical pregnancy and implantation rates remained similar between groups 2
Important caveat: The Italian Society of Endocrinology consensus states that myo-inositol should NOT be used to increase clinical pregnancy rate or live birth rate in subfertile women with or without PCOS 3
Pregnancy-Related Benefits
Myo-inositol has specific evidence-based applications during pregnancy in non-PCOS women:
Primary Prevention of Gestational Diabetes
- Myo-inositol can be used for primary prevention of gestational diabetes mellitus (GDM) in at-risk women 3
- However, it should NOT be used to improve pregnancy outcomes in women who already have GDM 3
Neural Tube Defect Prevention
- Myo-inositol can be added preconceptionally to folic acid in women with a previous NTD-complicated pregnancy to reduce the risk of neural tube defects in newborns 3
Neonatal Outcomes
- Myo-inositol used during pregnancy can reduce the risk of macrosomia and neonatal hypoglycemia in mothers at risk of GDM 3
Lack of Evidence for Other Indications
For women without PCOS, there is no evidence supporting myo-inositol use for:
- Menstrual irregularities (evidence only exists for PCOS populations) 3
- Metabolic or hormonal optimization outside of pregnancy contexts
- General fertility enhancement beyond the specific IVF gonadotropin-sparing effect
Clinical Approach
When considering myo-inositol in non-PCOS women:
For IVF patients: Consider 2g twice daily (with folic acid) starting 3 months before stimulation if cost-effectiveness of reducing gonadotropin doses is a priority, understanding this will not improve pregnancy success rates 2
For pregnancy planning in high-risk women: Use for GDM prevention or in women with prior NTD-affected pregnancies 3
Avoid use for menstrual regulation, ovulation induction, or general "fertility enhancement" in non-PCOS populations where evidence is lacking
The evidence base for inositol in non-PCOS women remains limited compared to PCOS populations, and most benefits are confined to specific reproductive medicine contexts rather than broad metabolic or hormonal effects. 3, 1